Doravirine

Doravirine
Clinical data
Trade names	Pifeltro
Other names	MK-1439
Routes of; administration	Oral[1]
ATC code	J05AG06 (WHO) ;
Legal status
Legal status	US: ℞-only ;
Identifiers
	IUPAC name 3-Chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydro-3-pyridinyl}oxy)benzonitrile;
CAS Number	1338225-97-0;
PubChem CID	58460047;
DrugBank	DB12301;
ChemSpider	28424197;
UNII	913P6LK81M;
KEGG	D10624;
ChEMBL	ChEMBL2364608;
PDB ligand	2KW (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID30158386 ;
ECHA InfoCard	100.234.454
Chemical and physical data
Formula	C17H11ClF3N5O3
Molar mass	425.75 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cn1c(n[nH]c1=O)Cn2ccc(c(c2=O)Oc3cc(cc(c3)Cl)C#N)C(F)(F)F;
	InChI InChI=1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28); Key:ZIAOVIPSKUPPQW-UHFFFAOYSA-N;

Doravirine (MK-1439) is a non-nucleoside reverse transcriptase inhibitor developed by Merck & Co. for use in the treatment of HIV/AIDS. In August 2018, the FDA approved doravine under the product name Pifeltro, and in a combination tablet, doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo).[2]

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.